-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to incomplete statistics, since 2022, more than 100 listed companies in the two A-share markets have been investigated by institutions.
Among them, pharmaceutical stocks are still favored by securities companies.
Among the 16 listed companies that have been investigated by over 100 institutions, pharmaceutical companies account for About one-third of the total, reaching 5, namely Mindray Medical, Huadong Medicine, Puluo Pharmaceutical, Jiu'an Medical and Teyi Pharmaceutical
.
Among them, the number of domestic medical device giant Mindray Medical has reached 427 since 2022
.
Mindray Medical's newly released information shows that from January 4th to January 7th, January 10th to January 14th, and January 17th, a total of 742 personnel from 430 institutions investigated companies
.
Judging from the research report, the issues that institutions are concerned about mainly include the core competitiveness of HyTest, which the company acquired last year, some blockbuster products recently launched, the reasons for the pressure on the company's overseas market growth in the second and third quarters of 2021, and the forecast for the fourth quarter.
and so on
.
In response to the problem that the performance of the online transmission company did not meet expectations, the company responded that it was pure nonsense
.
In 2021, the company's overall operating performance is good and its personnel are stable
.
The Shanghai branch will see strong performance growth in 2021, with more than 100% completion of sales tasks and a 46% year-on-year increase in revenue
.
"The company also said that the new domestic medical infrastructure projects in 2021 are progressing smoothly, and the expected orders have been placed by the end of 2021.
In 2022, the company expects that the main business will maintain steady growth, and the emerging business will continue to develop rapidly
.
The company will continue to Increase the R&D investment in high-potential emerging businesses such as animal medicine, minimally invasive surgery, orthopedics, and AED, accelerate the launch of new products, and continue to achieve rapid growth
.
The medical beauty business is favored by institutions, and 379 institutions have gathered for investigation since 2022.
The
company recently announced that on January 5, nearly 300 institutions and individuals including Goldman Sachs Group, Gao Yi Asset, BlackRock, and Sequoia Capital invested in A total of 525 people participated in the online conference of Huadong Medicine
.
This survey mainly focuses on the expansion of Huadong Medicine in the field of industrial microorganisms.
.
Huadong Medicine said that the company's industrial microbiology business can be divided into four major areas: pharmaceutical raw materials and high-end intermediates, special functional chemicals, large health and medical beauty raw materials, biological materials and enzyme preparations
.
In addition, Huachang Hi-Tech, which was acquired by the company at the end of last year, will be built into a new industrialization platform in the field of industrial microorganisms and a major production base for nucleoside products
.
In addition to Mindray Medical and Huadong Medicine, Puluo Pharmaceutical, Jiu'an Medical, and Teyi Pharmaceutical are also companies that have been investigated by 100 institutions since 2022, and 181, 161, and 101 institutions have been intensively investigated respectively.
It belongs to the subdivision fields of raw materials, in vitro diagnosis and traditional Chinese medicine
.
In addition to receiving high attention from institutional research, some pharmaceutical stocks such as Jiu'an Medical and Teyi Pharmaceutical have become popular stocks recently
.
It is reported that Teyi Pharmaceutical has increased by more than 40% since November 2021, and Jiu'an Medical has increased by more than 1000% since November 2021
.
The trading market shows that Jiu'an Medical has 5 daily limits after the year.
In the morning of January 18, Jiu'an Medical opened up 2.
64%, and it quickly fell by the limit in the afternoon.
As of the close of the day, Jiu'an Medical closed at 74.
53 yuan per share, a decrease of 10%.
%
.
According to Oriental Fortune, on January 18, the total transaction value of Jiu'an Medical was 8.
14 billion yuan, and the total market value was 35.
67 billion yuan
.
Among them, pharmaceutical stocks are still favored by securities companies.
Among the 16 listed companies that have been investigated by over 100 institutions, pharmaceutical companies account for About one-third of the total, reaching 5, namely Mindray Medical, Huadong Medicine, Puluo Pharmaceutical, Jiu'an Medical and Teyi Pharmaceutical
.
Among them, the number of domestic medical device giant Mindray Medical has reached 427 since 2022
.
Mindray Medical's newly released information shows that from January 4th to January 7th, January 10th to January 14th, and January 17th, a total of 742 personnel from 430 institutions investigated companies
.
Judging from the research report, the issues that institutions are concerned about mainly include the core competitiveness of HyTest, which the company acquired last year, some blockbuster products recently launched, the reasons for the pressure on the company's overseas market growth in the second and third quarters of 2021, and the forecast for the fourth quarter.
and so on
.
In response to the problem that the performance of the online transmission company did not meet expectations, the company responded that it was pure nonsense
.
In 2021, the company's overall operating performance is good and its personnel are stable
.
The Shanghai branch will see strong performance growth in 2021, with more than 100% completion of sales tasks and a 46% year-on-year increase in revenue
.
"The company also said that the new domestic medical infrastructure projects in 2021 are progressing smoothly, and the expected orders have been placed by the end of 2021.
In 2022, the company expects that the main business will maintain steady growth, and the emerging business will continue to develop rapidly
.
The company will continue to Increase the R&D investment in high-potential emerging businesses such as animal medicine, minimally invasive surgery, orthopedics, and AED, accelerate the launch of new products, and continue to achieve rapid growth
.
The medical beauty business is favored by institutions, and 379 institutions have gathered for investigation since 2022.
The
company recently announced that on January 5, nearly 300 institutions and individuals including Goldman Sachs Group, Gao Yi Asset, BlackRock, and Sequoia Capital invested in A total of 525 people participated in the online conference of Huadong Medicine
.
This survey mainly focuses on the expansion of Huadong Medicine in the field of industrial microorganisms.
.
Huadong Medicine said that the company's industrial microbiology business can be divided into four major areas: pharmaceutical raw materials and high-end intermediates, special functional chemicals, large health and medical beauty raw materials, biological materials and enzyme preparations
.
In addition, Huachang Hi-Tech, which was acquired by the company at the end of last year, will be built into a new industrialization platform in the field of industrial microorganisms and a major production base for nucleoside products
.
In addition to Mindray Medical and Huadong Medicine, Puluo Pharmaceutical, Jiu'an Medical, and Teyi Pharmaceutical are also companies that have been investigated by 100 institutions since 2022, and 181, 161, and 101 institutions have been intensively investigated respectively.
It belongs to the subdivision fields of raw materials, in vitro diagnosis and traditional Chinese medicine
.
In addition to receiving high attention from institutional research, some pharmaceutical stocks such as Jiu'an Medical and Teyi Pharmaceutical have become popular stocks recently
.
It is reported that Teyi Pharmaceutical has increased by more than 40% since November 2021, and Jiu'an Medical has increased by more than 1000% since November 2021
.
The trading market shows that Jiu'an Medical has 5 daily limits after the year.
In the morning of January 18, Jiu'an Medical opened up 2.
64%, and it quickly fell by the limit in the afternoon.
As of the close of the day, Jiu'an Medical closed at 74.
53 yuan per share, a decrease of 10%.
%
.
According to Oriental Fortune, on January 18, the total transaction value of Jiu'an Medical was 8.
14 billion yuan, and the total market value was 35.
67 billion yuan
.
